{"id":195092,"date":"2026-08-11T12:59:49","date_gmt":"2026-08-11T07:29:49","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=195092"},"modified":"2026-08-11T12:59:50","modified_gmt":"2026-08-11T07:29:50","slug":"astrazeneca-india-q1-results-fy27-pat-37-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/","title":{"rendered":"AstraZeneca India Q1 FY27 Results: Revenue Rs 682 Cr, PAT Rs 37 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>AstraZeneca India Q1 FY27 results declared August 10, 2026. Revenue Rs 682 Cr (+29.73% YoY). PAT Rs 37 Cr (-32.06% YoY). CMP Rs 8090.0 (-1.23%).<\/em><\/p>\n<p>AstraZeneca India Q1 FY27 results were declared on August 10, 2026 on a standalone basis. Revenue expanded +29.73% YoY to Rs 682 Cr from Rs 526 Cr in Q1 FY26. The broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit stood at Rs 43 Cr (-32.27% YoY). PAT came in at Rs 37 Cr (-32.06% YoY), reflecting the key financial metrics of AstraZeneca India Q1 FY27 results.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=astrazeneca-india-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#AstraZeneca_India_Q1_FY27_Financial_Highlights\" title=\"AstraZeneca India Q1 FY27 Financial Highlights\">AstraZeneca India Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#AstraZeneca_India_Q1_FY27_Performance_Analysis\" title=\"AstraZeneca India Q1 FY27 Performance Analysis\">AstraZeneca India Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Key_Business_Factors_in_AstraZeneca_India_Q1_FY27_Results\" title=\"Key Business Factors in AstraZeneca India Q1 FY27 Results\">Key Business Factors in AstraZeneca India Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Revenue_Expansion_in_Q1_FY27\" title=\"Revenue Expansion in Q1 FY27\">Revenue Expansion in Q1 FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Margin_Pressure_from_Cost_Headwinds\" title=\"Margin Pressure from Cost Headwinds\">Margin Pressure from Cost Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#PAT_Trajectory_and_Profitability\" title=\"PAT Trajectory and Profitability\">PAT Trajectory and Profitability<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#FY27_Outlook_for_AstraZeneca_India\" title=\"FY27 Outlook for AstraZeneca India\">FY27 Outlook for AstraZeneca India<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#AstraZeneca_India_Stock_Performance_After_Q1_FY27_Results\" title=\"AstraZeneca India Stock Performance After Q1 FY27 Results\">AstraZeneca India Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Key_Risks_for_AstraZeneca_India\" title=\"Key Risks for AstraZeneca India\">Key Risks for AstraZeneca India<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Frequently_Asked_Questions_on_AstraZeneca_India_Q1_FY27_Results\" title=\"Frequently Asked Questions on AstraZeneca India Q1 FY27 Results\">Frequently Asked Questions on AstraZeneca India Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#When_were_AstraZeneca_India_Q1_FY27_results_declared\" title=\"When were AstraZeneca India Q1 FY27 results declared?\">When were AstraZeneca India Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#What_was_AstraZeneca_India_revenue_in_Q1_FY27\" title=\"What was AstraZeneca India revenue in Q1 FY27?\">What was AstraZeneca India revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#What_was_AstraZeneca_India_PAT_in_Q1_FY27\" title=\"What was AstraZeneca India PAT in Q1 FY27?\">What was AstraZeneca India PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#Did_AstraZeneca_India_declare_a_dividend_in_Q1_FY27\" title=\"Did AstraZeneca India declare a dividend in Q1 FY27?\">Did AstraZeneca India declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#What_is_the_FY27_outlook_for_AstraZeneca_India\" title=\"What is the FY27 outlook for AstraZeneca India?\">What is the FY27 outlook for AstraZeneca India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-india-q1-results-fy27-pat-37-crore\/#How_did_AstraZeneca_India_stock_react_to_Q1_FY27_results\" title=\"How did AstraZeneca India stock react to Q1 FY27 results?\">How did AstraZeneca India stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"AstraZeneca_India_Q1_FY27_Financial_Highlights\"><\/span><strong>AstraZeneca India Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #fff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">AstraZeneca India Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">682<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">526<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+29.73%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">43<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">64<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-32.27%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">37<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">55<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-32.06%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\" colspan=\"3\">Standalone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"AstraZeneca_India_Q1_FY27_Performance_Analysis\"><\/span><strong>AstraZeneca India Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>AstraZeneca India Q1 FY27 results reflect under-pressure fundamentals. Revenue momentum were evident with the top line reaching Rs 682 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit contracted -32.27% YoY. PAT of Rs 37 Cr reflects -32.06% YoY movement. Investors tracking AstraZeneca India Q1 FY27 results will note these as key FY27 milestones.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_AstraZeneca_India_Q1_FY27_Results\"><\/span><strong>Key Business Factors in AstraZeneca India Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Expansion_in_Q1_FY27\"><\/span><strong>Revenue Expansion in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>AstraZeneca India Q1 FY27 results show revenue expanding +29.73% YoY to Rs 682 Cr from Rs 526 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margin_Pressure_from_Cost_Headwinds\"><\/span><strong>Margin Pressure from Cost Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in AstraZeneca India Q1 FY27 results stood at Rs 43 Cr (-32.27% YoY). Input cost inflation and competitive dynamics weighed on operating profitability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Trajectory_and_Profitability\"><\/span><strong>PAT Trajectory and Profitability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT in AstraZeneca India Q1 FY27 results was Rs 37 Cr (-32.06% YoY), reflecting near-term operational challenges.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was declared alongside AstraZeneca India Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_AstraZeneca_India\"><\/span><strong>FY27 Outlook for AstraZeneca India<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following AstraZeneca India Q1 FY27 results, management has focused on a recovery-driven strategy centred on cost reduction, revenue diversification, and return to profitability in the pharmaceuticals segment. Investors tracking AstraZeneca India Q1 FY27 results should consult a SEBI-registered financial advisor.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"AstraZeneca_India_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>AstraZeneca India Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track AstraZeneca India live price and get daily stock recommendations.<\/em><\/p>\n<p>AstraZeneca India shares were trading lower at Rs 8090.0 (-1.23%) on August 10, 2026, reflecting investor sentiment on AstraZeneca India Q1 FY27 results and the near-term sector outlook. The CMP of Rs 8090.0 on the results date reflects broader sentiment toward the pharmaceuticals space.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_AstraZeneca_India\"><\/span><strong>Key Risks for AstraZeneca India<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained margin compression and limited near-term earnings visibility may delay re-rating.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>AstraZeneca India Q1 FY27 results reflect under-pressure performance with revenue at Rs 682 Cr and PAT at Rs 37 Cr on a Standalone basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_AstraZeneca_India_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on AstraZeneca India Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_AstraZeneca_India_Q1_FY27_results_declared\"><\/span><strong>When were AstraZeneca India Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> AstraZeneca India Q1 FY27 results were declared on August 10, 2026, covering the April\u2013June 2026 quarter on a Standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_AstraZeneca_India_revenue_in_Q1_FY27\"><\/span><strong>What was AstraZeneca India revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in AstraZeneca India Q1 FY27 results was Rs 682 Cr, +29.73% YoY from Rs 526 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_AstraZeneca_India_PAT_in_Q1_FY27\"><\/span><strong>What was AstraZeneca India PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in AstraZeneca India Q1 FY27 results was Rs 37 Cr (-32.06% YoY).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_AstraZeneca_India_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did AstraZeneca India declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was announced alongside AstraZeneca India Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_AstraZeneca_India\"><\/span><strong>What is the FY27 outlook for AstraZeneca India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Management has guided operational restructuring and return to profitability for FY27. Sector demand and execution will be key monitorables.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_AstraZeneca_India_stock_react_to_Q1_FY27_results\"><\/span><strong>How did AstraZeneca India stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> AstraZeneca India shares were lower at Rs 8090.0 (-1.23%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca India Q1 FY27 results: Revenue Rs 682 Cr (+29.73% YoY), PAT Rs 37 Cr (-32.06% YoY). Key highlights, analysis and FY27 outlook.<\/p>\n","protected":false},"author":36,"featured_media":195091,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-195092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["195091"],"_edit_lock":["1786433393:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_title":["AstraZeneca India Q1 FY27 Results: Revenue, PAT &amp; Key Highlights"],"rank_math_description":["AstraZeneca India Q1 FY27 results: Revenue Rs 682 Cr (+29.73% YoY), PAT Rs 37 Cr (-32.06% YoY). Key highlights, analysis and FY27 outlook."],"rank_math_focus_keyword":["AstraZeneca India Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35874"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/astrazeneca-india-q1-results-fy27-pat-37-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=195092"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195092\/revisions"}],"predecessor-version":[{"id":196607,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195092\/revisions\/196607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/195091"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=195092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=195092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=195092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}